← All trials
NCT04388371
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2019
- Primary completion
- Oct 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- May 14, 2020
- Last posted
- May 14, 2020
- Enrollment
- 5
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Vanderbilt UniversityLead sponsor
- Vanderbilt UniversityOverall official - principal investigator
- Vanderbilt UniversityReponsible party - principal investigator
- The LAM FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.